SurgePays (SURG): Analyzing the -21% Drop Over the Past Month and -67% Quarterly Decline
Key Takeaways
- SURG stock declined approximately -21% over the past 30 days amid broader market pressures and company-specific challenges like delayed filings.
- Over the past quarter, the stock fell around -67%, reflecting persistent losses despite revenue growth in prior quarters.
- Recent Q3 2025 earnings showed 292% YoY revenue surge to $18.7M but widened net losses to $7.5M and EPS miss, eroding investor confidence.
- Delayed 2025 10-K filing due to audit issues added uncertainty, contributing to downward price movement.
- Launch of stored value and loyalty platform signals fintech expansion, but operational inefficiencies and cash burn remain key drags.
- Microcap volatility and low trading volumes amplified the downtrend in a risk-off environment.
Understanding SurgePays (SURG) and Its Place in the Market
SurgePays, Inc. (SURG) operates as a financial technology and telecom company, focusing on mobile virtual network operator (MVNO) services and point-of-sale platforms. It delivers prepaid wireless top-ups, mobile broadband, and fintech solutions such as ACH banking to convenience stores, with a target market of underserved and subprime consumers. The core model relies on a nationwide retail network to offer wireless plans under brands like Torch Wireless—supported by the Lifeline government subsidy program—and LinkUp Mobile, complemented by marketing and transaction services.
In the competitive fintech and telecom landscapes, SURG sets itself apart with an integrated ecosystem aimed at independent retailers in rural areas, where gaps in traditional banking and connectivity endure. That said, thin margins in prepaid services and dependence on government programs introduce operational risks, which help explain the recent weakness in the stock price despite its revenue potential.
SURG Stock Performance: The Past 30 Days and Quarterly View
In the last 30 days, SURG stock fell from a closing price of $0.85 on March 10, 2026, to $0.67 on April 10, 2026, marking a -21% decline. The price action was volatile yet range-bound, fluctuating between $0.65 and $0.88, with consistent downward pressure on low volumes that averaged under 100K shares daily.
Looking at the past quarter, the stock plunged -67% from $2.04 around January 12, 2026, to its current $0.67 level. This trend-driven selloff gained momentum in January and February, paused briefly in March, and then resumed lower, driven by earnings shortfalls and filing delays.
Key Factors Behind the 30-Day Decline in SURG
The -21% drop over the past 30 days was largely triggered by the delayed Form 10-K filing for fiscal 2025, announced on March 31, 2026, stemming from audit completion issues. This development sparked worries about financial transparency, weighing heavily on the microcap stock in a cautious market environment.
The April 2 launch of a stored value and loyalty platform across its retail network provided some counterbalance, but it wasn't enough to shift the overall sentiment. I also checked this using Tickeron’s AI Screener to gauge how SURG stacks up against industry peers, and no significant analyst upgrades or sector tailwinds appeared. Thin liquidity exacerbated the downside, while macro elements like interest rate uncertainty added indirect pressure on growth-oriented stocks like this one.
Quarterly Drivers of SURG's -67% Slide
The steep -67% quarterly decline was primarily fueled by the Q3 2025 earnings release on November 12, 2025, which reported a $7.5M net loss even as revenues jumped 292% year-over-year to $18.7M, thanks to MVNO expansion. The EPS shortfall (-$0.38 versus -$0.12 expected) underscored gross losses of $2.6M and cash burn reaching $2.5M, pointing to challenges in scaling the business.
Institutional selling and broader microcap sector headwinds piled on, without any notable competitive victories or macroeconomic relief. Telecom demand remained stable through Lifeline, but fintech inefficiencies and underutilized operations diminished value. The net result has been investors pulling back from this profile of unprofitable growth.
Exploring Tickeron’s Trending AI Robots
In my own research process, I often turn to Tickeron’s Trending AI Robots page, which highlights the platform's top-performing AI trading bots out of hundreds available. These bots scan thousands of tickers using strategies such as momentum, mean reversion, and scalping. Filtered by recent win rates, Sharpe ratios, and market relevance, they offer a way to automate trades across timeframes from intraday to swing. With transparent metrics like average returns and drawdowns, this neutral, data-driven resource has proven useful for analyzing volatile microcaps like SURG. One thing that stands out is how it helps identify bots suited to current conditions without hype.
What to Watch in SURG's Outlook Moving Forward
From what I see, investors need to keep an eye on the delayed Q4 and full-year 2025 earnings call scheduled for April 14, 2026, which should provide updates on the 10-K filing, cash position, and the $225M revenue guidance for 2026. Monitoring MVNO growth in Lifeline and LinkUp will be crucial, especially with government funding stability in play.
Progress on the fintech rollout—particularly adoption of the stored value platform and margins at Clearline—could indicate operational gains. Broader trends like rural broadband demand and potential rate cuts might offer support, though cash burn, dilution risks from capital raises, and competition in prepaid services warrant close attention. I’m watching this closely for signs of stabilization.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SURG's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SURG turned positive on September 04, 2026. Looking at past instances where SURG's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SURG's RSI Indicator exited the oversold zone, 34 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 66 cases where SURG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +7.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where SURG advanced for three days, in 205 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
SURG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SURG as a result. In 80 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SURG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for SURG entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. SURG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SURG's P/B Ratio (344.828) is very high in comparison to the industry average of (10.715). P/E Ratio (38.250) is within average values for comparable stocks, (33.181). Projected Growth (PEG Ratio) (0.474) is also within normal values, averaging (8.005). Dividend Yield (0.000) settles around the average of (0.027) among similar stocks. P/S Ratio (0.048) is also within normal values, averaging (5.777).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SURG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MajorTelecommunications
Advertisement